IPO filing research

INNOCAN PHARMA Corp

Pharmaceutical Preparations · INNP

follow-on amended NYSE American FWP

INNOCAN PHARMA Corp IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: FWP on 2026-04-03. Current deal snapshot: exchange NYSE American.

Filing Timeline

SEC EDGAR

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's FWP filing details an initial public offering of 3,750,000 units, each containing one common share and one warrant, with an anticipated price range of $5.00-$6.00 per unit. The offering includes pre-funded units for investors exceeding ownership thresholds, along with a 65-for-1 reverse share split effective September 5, 2025. The company plans to list on NYSE American and emphasizes its status as an emerging growth company and foreign private issuer.

2026-04-03 · 0001493152-26-015156

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Price $5.50 · Range $5.00 to $6.00 · 3,750,000 shares

Common Share · Exchange NYSE American · Ticker INNP · Over-allotment 562,500 · Each unit consists of one common share and one warrant · Each warrant has an exercise price of $6.875 per share, exercisable immediately, and expires in 5 years · Use of proceeds Working capital and general corporate purposes · Flags foreign_private_issuer, units, warrants · Underwriters ThinkEquity

Innocan Pharma Corporation is conducting an initial public offering (IPO) of up to 3,750,000 units, each consisting of one common share and one warrant, with an anticipated price range of $5.00 to $6.00 per unit. The offering also includes up to 3,750,000 pre-funded units for investors exceeding ownership thresholds. The company plans to list its shares on the NYSE American and is an emerging growth company and foreign private issuer, subject to reduced reporting requirements. The filing reflects a 65-for-1 reverse share split effective September 5, 2025.

2026-04-03 · 0001493152-26-015152

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's FWP filing outlines an initial public offering of 3,750,000 units, each consisting of one common share and one warrant, with an anticipated price range of $5.00-$6.00 per unit. The offering includes up to 3,750,000 pre-funded units for investors exceeding ownership thresholds, along with warrants exercisable at $6.875 per share. The company, an emerging growth company and foreign private issuer, plans to list on NYSE American. A 65-for-1 reverse share split was effective September 5, 2025, and the offering price will be determined by market conditions.

2026-03-16 · 0001493152-26-010291

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows RW in the pre-IPO sequence.

Range $5.00 to $6.00 · 3,750,000 shares

Common Shares · Exchange NYSE American · Ticker INNP · Over-allotment 562,500 · Each unit consists of one common share and one warrant to purchase one common share · Each warrant has an exercise price of $6.875 (125% of the public offering price per unit), is immediately exercisable, and expires five years from issuance · Use of proceeds Proceeds will be used for general corporate purposes · Flags foreign_private_issuer, units, warrants · Underwriters ThinkEquity

Innocan Pharma Corp. is conducting an initial public offering (IPO) of up to 3,750,000 units, each consisting of one common share and one warrant, with an anticipated price range of $5.00 to $6.00 per unit. The offering includes up to 3,750,000 pre-funded units for investors exceeding ownership thresholds, along with warrants. The company plans to list its securities on the NYSE American under symbols INNP and INNPW. The filing reflects a 65-for-1 reverse share split effective September 5, 2025, and confirms the company's status as an emerging growth company and foreign private issuer.

2026-03-16 · 0001493152-26-010255

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows EFFECT and ends the active registration process.

Innocan Pharma Corporation has requested the withdrawal of its Registration Statement on Form F-1, effective immediately. The company decided not to proceed with its public offering and confirmed no securities were sold under the registration. The withdrawal aligns with the public interest and investor protection, with a request to credit fees paid to the SEC for future use.

2026-02-23 · 0001493152-26-007688

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows F-1/A and marks the registration effective.

INNOCAN PHARMA Corp has received effectiveness for its IPO registration statement on Form F-1, dated January 30, 2026. The filing includes an updated Exhibit 5.1 and amended exhibit index, with no substantive changes to the prospectus content. The company remains an emerging growth company and maintains indemnification provisions for directors and officers.

2026-01-30 · 9999999995-26-000367

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

30,492 shares

Class A and Class B · Each unit consists of one common share and one or more warrants with varying exercise prices and terms · Units include Class A and Class B warrants exercisable at CAD$20.15-CAD$28.6 for 2-5 year terms · Underwriters Research Capital Corporation

Innocan Pharma Corp's F-1/A filing represents an amendment to its initial registration statement, focusing on updating exhibits and incorporating additional details on corporate governance, indemnification provisions, and recent private placement activities. The filing highlights the company's ongoing efforts to comply with regulatory requirements and prepare for its initial public offering (IPO), including disclosures about unregistered securities sales and legal counsel engagements.

2026-01-07 · 0001493152-26-000726

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's FWP outlines an IPO of 2,350,000 units, each containing one common share and one warrant. The offering price ranges from $5.00 to $6.00 per unit, with warrants exercisable at $6.875 (125% of the unit price). The company plans to list on NYSE American and has implemented a 65-for-1 reverse share split. As an emerging growth company and foreign private issuer, it faces reduced reporting requirements and governance practices, including no majority of independent directors post-offering.

2026-01-06 · 0001493152-26-000541

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Range $5.00 to $6.00 · 2,350,000 shares

Common Shares · Exchange NYSE American · Ticker INNP · Over-allotment 352,500 · Each unit consists of one common share and one warrant · Warrants exercisable at $6.875 per share, expiring 5 years from issuance · Flags foreign_private_issuer, units, warrants · Underwriters ThinkEquity

Innocan Pharma Corp. is conducting an initial public offering (IPO) of 2,350,000 units, each consisting of one common share and one warrant to purchase a common share. The offering price is expected to range between $5.00 and $6.00 per unit, with warrants exercisable at $6.875 per share. The company has applied to list its securities on the NYSE American under the symbols INNP and INNPW. The filing reflects a 65-for-1 reverse share split effective September 5, 2025, and includes updated details on underwriting terms, risk factors, and corporate structure as an emerging growth company and foreign private issuer.

2026-01-06 · 0001493152-26-000539

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp. is conducting an initial public offering (IPO) of 2,350,000 units, each consisting of one common share and one warrant to purchase a common share. The offering price is expected to range between $5.00 and $6.00 per unit, with warrants exercisable at $6.875 per share. The company plans to list its shares and warrants on the NYSE American under symbols INNP and INNPW. The filing reflects a 65-for-1 reverse share split effective September 5, 2025, and highlights the company's status as an emerging growth company and foreign private issuer with reduced reporting requirements.

2025-12-10 · 0001493152-25-027063

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Price $5.50 · Range $5.00 to $6.00 · 2,350,000 shares

Common Shares · Exchange NYSE American LLC · Ticker INNP · Over-allotment 352,500 · Each unit consists of one common share and one warrant to purchase one common share · Warrants to purchase common shares at $6.875 per share, exercisable immediately, expiring in 5 years · Use of proceeds Proceeds will be used for general corporate purposes · Flags foreign_private_issuer, units, warrants · Underwriters ThinkEquity

Innocan Pharma Corp. is conducting an initial public offering (IPO) of 2,350,000 units, each consisting of one common share and one warrant to purchase a common share. The offering price is expected to range between $5.00 and $6.00 per unit, with warrants exercisable at $6.875 per share. The company has implemented a 65-for-1 reverse share split effective September 5, 2025, and plans to list its shares on the NYSE American under the symbols INNP and INNPW. The offering includes a 45-day option for underwriters to purchase additional shares. The company is an emerging growth company and a foreign private issuer, subject to reduced reporting requirements.

2025-12-10 · 0001493152-25-027017

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

30,492 shares

Common · Units consist of common shares and warrants · Warrants include Class A and Class B with exercise prices ranging from CAD$18.85 to CAD$28.60 and terms up to 5 years

Innocan Pharma Corporation filed an F-1/A registration statement amendment, incorporating Rule 473(b) language for automatic effectiveness and updating Exhibit 23.1. The filing includes detailed indemnification provisions for directors/officers, recent unregistered securities sales, and underwriting terms. The company remains an emerging growth entity and has ongoing private placement activities.

2025-10-22 · 0001493152-25-018908

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp. is conducting an initial public offering (IPO) of 1,088,157 units, each consisting of one common share and one warrant to purchase a common share. The offering price is set at $13.962 per unit, reflecting a reverse share split effective September 5, 2025. The company plans to list its securities on Nasdaq under the symbols INNP and INNPW, contingent on approval. The filing emphasizes risks associated with the offering, including market volatility and the company's status as an emerging growth company and foreign private issuer.

2025-10-01 · 0001493152-25-016465

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Price $13.96 · 1,088,157 shares

Common Share · Exchange Nasdaq · Ticker INNP · Over-allotment 163,224 · Each unit includes one common share and one warrant · Warrants exercisable at $17.4525 per share, expire in 5 years · Flags foreign_private_issuer, units · Underwriters ThinkEquity

Innocan Pharma Corp's F-1/A filing represents an updated registration statement for its initial public offering (IPO), detailing the proposed sale of 1,088,157 units consisting of common shares and warrants. The filing includes an amended reverse stock split, revised pricing details, and additional disclosures about the company's status as an emerging growth company and foreign private issuer. The offering aims to list shares on Nasdaq, with underwriting terms and risk factors outlined. The company also highlights its operations in consumer wellness and pharmaceuticals, along with financial disclosures under IFRS.

2025-09-30 · 0001493152-25-016393

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows F-1/A and registers the class of securities for exchange listing.

Innocan Pharma Corporation filed Form 8-A12B to register its common shares, no par value, on The Nasdaq Stock Market LLC. The filing incorporates by reference the share capital description from its prior Registration Statement on Form F-1 (File No. 333-288899), indicating the company is advancing toward its IPO process. The previous filing (FWP) was a preliminary prospectus, suggesting this 8-A12B represents a formal step in the registration process.

2025-09-22 · 0001493152-25-014469

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS and supplements the active offering with updated prospectus details.

Innocan Pharma Corp filed a Free Writing Prospectus (FWP) on September 12, 2025, relating to a preliminary prospectus dated the same day. The filing references registration number 333-288899, with the previous FWP dated September 5, 2025, under the same registration number.

2025-09-12 · 0001493152-25-013131

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

First tracked pre-IPO filing for this issuer.

Innocan Pharma Corp. is conducting an initial public offering (IPO) of 1,538,462 units, each consisting of one common share and one warrant to purchase a common share, with an estimated offering price of $9.875 per unit. The offering follows a 65-for-1 reverse share split effective September 5, 2025, and includes a 45-day option for underwriters to purchase additional shares/warrants. The company plans to list on Nasdaq under symbols INNP (common shares) and INNPW (warrants). It is an emerging growth company and foreign private issuer with reduced reporting requirements and no planned majority of independent directors.

2025-09-05 · 0001493152-25-012694

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Price $9.88 · 1,538,462 shares

Common · Exchange Nasdaq · Over-allotment 230,770 · Each consisting of One Common Share and One Warrant to Purchase One Common Share · Each warrant has an exercise price of $12.3438, is immediately exercisable, and expires five years from the date of issuance · Use of proceeds for general corporate purposes · Flags foreign_private_issuer, units, warrants · Underwriters ThinkEquity

Innocan Pharma Corp. filed an F-1/A registration statement for its initial public offering (IPO) of 1,538,462 units, each consisting of one common share and one warrant. The offering price is set at $9.875 per unit, based on the September 2, 2025, closing price on the Canadian Securities Exchange (CSE). The filing includes a 65-for-1 reverse share split effective September 5, 2025, and details about listing on Nasdaq. The company also highlights its status as an emerging growth company and foreign private issuer, with reduced reporting requirements and non-independent board governance.

2025-09-05 · 0001493152-25-012688

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Price $9.88 · 1,538,462 shares

Common Share and One Warrant to Purchase One Common Share · Exchange Nasdaq · Ticker INNP · Over-allotment 230,770 · Each Unit consists of one Common Share and one Warrant · Each warrant has an exercise price of $12.3438, is immediately exercisable, and expires in 5 years · Use of proceeds Proceeds will be used for general corporate purposes, including working capital and potential acquisitions · Flags foreign_private_issuer, units, warrants · Underwriters ThinkEquity

Innocan Pharma Corp's updated F-1/A filing details its initial public offering of 1,538,462 units (each containing one common share and one warrant) at an estimated price of $9.875 per unit, following a proposed 65-for-1 reverse share split. The filing confirms plans to list on Nasdaq and includes revised financial disclosures, underwriter details, and risk factors. Compared to the previous F-1, this amendment updates pricing, share structure, and listing information.

2025-08-04 · 0001493152-25-011564

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Price $9.75 · 1,538,461 shares

Common Share · Exchange Nasdaq · Ticker INNP · Over-allotment 230,770 · Each Unit consists of one Common Share and one Warrant to Purchase One Common Share · Each Warrant entitles the holder to purchase one Common Share · Use of proceeds for general corporate purposes · Flags units, warrants, foreign_private_issuer · Underwriters ThinkEquity

Innocan Pharma Corp. is conducting an IPO with 1,538,461 units, each containing one common share and one warrant, at an estimated price of $9.75. The offering includes a 65-for-1 reverse share split, with shares to be listed on Nasdaq under INNP. The company is an emerging growth company and foreign private issuer, subject to reduced reporting requirements. The filing includes underwriter details (ThinkEquity) and risk factors related to market volatility, reverse split impact, and regulatory compliance.

2025-07-23 · 0001641172-25-020718

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corp's DRS/A filing details its initial public offering (IPO) of 961,538 common shares at an estimated price of $10.40, following a 65-for-1 reverse split. The company plans to list on Nasdaq under the symbol INNP, contingent on meeting listing requirements. It highlights its status as an emerging growth company and foreign private issuer, with reduced reporting requirements and non-independent board governance. The filing emphasizes risks related to market volatility, IFRS financial reporting, and potential discrepancies between offering and current market prices.

2025-06-20 · 0001641172-25-015836

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corp. is conducting an initial public offering (IPO) of common shares, aiming to list on Nasdaq under an unspecified symbol. The company operates in two segments: Pharmaceuticals (developing cannabinoid-based drug delivery technologies) and Consumer Wellness (online sales via a subsidiary). The IPO price range is unspecified, with shares currently trading on the Canadian Securities Exchange (CSE) and other markets. The company is an emerging growth company and foreign private issuer, subject to reduced reporting requirements. The offering includes underwriting discounts and a 45-day option for over-allotments.

2025-05-15 · 0001641172-25-010821

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corp. is conducting an initial public offering (IPO) of common shares, aiming to list on Nasdaq under the symbol 'INNO'. The company operates in two segments: Pharmaceuticals (drug delivery technologies using cannabinoids) and Consumer Wellness (online sales). The offering price is unspecified, with proceeds intended for general corporate purposes. The filing highlights risks related to market volatility, regulatory challenges, and the company's status as an emerging growth company and foreign private issuer.

2025-05-12 · 0001641172-25-009654

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corp is conducting an initial public offering (IPO) of common shares, aiming to list on Nasdaq under the symbol 'INNO'. The company, an emerging growth company and foreign private issuer, operates in two segments: Pharmaceuticals and Consumer Wellness. The offering price range and underwriting details are outlined, with the company emphasizing risks associated with its early-stage drug development and market volatility.

2025-05-01 · 0001641172-25-008062

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Innocan Pharma Corp's DRS/A filing outlines the initial public offering (IPO) of its common shares, with an anticipated price range between $ and $ per share. The company plans to list on a national securities exchange under the symbol . The filing highlights the company's status as an emerging growth company and foreign private issuer, subject to reduced reporting requirements. The IPO follows recent trading on the Canadian Securities Exchange (CSE), OTCQB, and Frankfurt Stock Exchange (FSE), with share prices noted as of March 27, 2025. The offering is conditional on the shares qualifying for national exchange listing.

2025-03-28 · 0001641172-25-001089

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Innocan Pharma Corporation is conducting its initial public offering (IPO) of common shares, aiming to list on a U.S. national securities exchange. The company operates in two segments: Pharmaceuticals, focused on cannabinoid-based drug delivery technologies, and Consumer Wellness, involving online sales. The IPO price range is unspecified, and the company is an emerging growth company under the JOBS Act, subject to reduced reporting requirements. Its current shares trade on the Canadian Securities Exchange (CSE) and OTCQB, with no prior filings referenced.

2024-12-31 · 0001493152-24-052663